Alto Neuroscience, Inc. (ANRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.18B
Last updated: Nov 17, 2026 at 11:04 AM ET
Alto Neuroscience, Inc. (ANRO) Stock Forecast
Analysts expect Alto Neuroscience (ANRO) to earn -$2.49 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 10 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.09, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 10 | 90.9% |
| Hold | 1 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Dec 31, 2026
- -$2.49
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.09
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.49 | -$2.49 to -$2.48 | 2 |
| Dec 31, 2027 | -$3.09 | -$4.10 to -$2.30 | 6 |
Quarterly Estimates
The EPS consensus falls from -$0.65 for the quarter ending Dec 31, 2026 to -$0.74 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.65 | -$0.78 to -$0.54 | 13 |
| Mar 31, 2027 | -$0.74 | -$1.02 to -$0.57 | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.49 | -$2.92 | -$2.92 | -$2.92 | -$3.17 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.09 | -$3.19 | -$3.29 | -$3.29 | -$3.48 | N/A |
| Quarter ending Mar 31, 2027 | -$0.74 | -$0.77 | -$0.80 | -$0.80 | -$0.80 | N/A |
Frequently Asked Questions About ANRO
What is the ANRO stock forecast?
Consensus analyst estimates put Alto Neuroscience's EPS at -$2.49 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.
How do analysts rate ANRO stock?
Of 11 analysts covering Alto Neuroscience, 0 rate it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ANRO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.49, with estimates from -$2.49 to -$2.48 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.09, with estimates from -$4.10 to -$2.30 from 6 analysts.
How many analysts cover ANRO?
11 analysts rate Alto Neuroscience stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ANRO pages: Overview, Earnings, Forecast, Financials, Competitors